Key takeaways:
Lipoprotein(a), or Lp(a), is a form of LDL (“bad”) cholesterol with an extra protein attached. High levels can raise your risk of heart attack and stroke.
No medications are currently FDA approved to lower Lp(a). But researchers are studying several medications to lower Lp(a) levels.
One experimental medication called pelacarsen showed a lot of promise. It lowered Lp(a) by about 80%. But it didn’t reduce the number of heart attacks or strokes.
Diet and lifestyle can affect regular LDL cholesterol levels, but Lp(a) levels are mostly determined by your genes. Diet and exercise usually don’t change Lp(a).
Researchers have been hard at work trying to develop medications to lower lipoprotein(a), also known as Lp(a). Lp(a) is a form of low-density lipoprotein (LDL) cholesterol — the bad type of cholesterol — except it has a slightly different structure that makes it even more harmful. If you have too much Lp(a), it can raise your risk of health issues such as heart disease, stroke, and heart valve problems.
Unlike other types of cholesterol, high levels of Lp(a) don’t usually respond to medications like statins. Healthy lifestyle changes like good nutrition and exercise also have no impact on Lp(a).
But there’s hope on the horizon. This article will review the medications and clinical trials that may lead to new treatment options.
Overview of medications for lipoprotein(a) in clinical trials
Before we dive into the details of the treatments, the chart below provides a brief overview of the medications in clinical trials. That means that currently none are available by prescription. Some are in phase 2 trials, where researchers test a medication in a small group of people to see how well it works and look for side effects. Others are in phase 3, which involve more people and confirm the medication’s benefits and safety. Phase 3 is usually the last major stage of testing before a medication manufacturer applies for FDA approval.
Treatment | How it’s given | Effect on Lp(a) | Current status |
Pelacarsen | Injection under the skin every month | Up to 80% reduction | Phase 3 trials showed no reduction in major heart or stroke events. |
Olpasiran | Injection under the skin every 12-24 weeks | More than 95% reduction | Phase 3 trials are in process. |
Zerlasiran | Injection under the skin every 16-24 weeks | 80%-85% reduction | Phase 2 is complete. |
Lepodisaran | Injection under the skin every 6 months | About 95% reduction | Phase 3 trials are in process. |
Muvalaplin | Once daily pill | Up to 86% reduction | Phase 3 trials are in process. |
HRS-5346 / MK-7262 | Pill | Up to 86% reduction | Phase 2 in process. |
1. Pelacarsen
Pelacarsen is an injectable medication that lowered Lp(a) by as much as 80% in phase 2 trials. Pelacarsen blocks instructions in the liver to make apo(a), a protein needed to build Lp(a). With less of this protein, your body makes less Lp(a).
Because pelacarsen had such a big impact on Lp(a), it seemed likely that it would cut heart disease and stroke risk. So it entered a 7-year phase 3 trial that included over 8,000 people with heart disease. Even though it lowered Lp(a), pelacarsen showed no benefit on heart disease or stroke outcomes.
Why didn’t the treatment help? Researchers have some ideas:
One possibility is that high Lp(a) signals a higher risk of heart disease but doesn’t directly cause it.
The people in the phase 3 trial were already taking cholesterol medication like statins. So this may have left little room for the new treatment to provide more benefit.
Some experts believe that the treatment could have been started too late to make a difference.
There are still some studies of pelacarsen that are in progress. One is looking at whether the medication can slow the narrowing of the aortic valve in people with high Lp(a) and aortic stenosis.
2. Olpasiran
Olpasiran is a different Lp(a) medication that’s currently in phase 3 studies. It has some similarities to pelacarsen, but it works slightly differently in the liver.
Olpasiran is injected under the skin once every 12 to 24 weeks (3 to 6 months). One study found that the effects of olpasiran lasted for nearly a year after the last dose.
Preliminary data for olpasiran is encouraging. A recent phase 2 study suggests that doses of 75 mg or higher can lower Lp(a) levels by over 95%. A phase 3 trial with 7,200 people started in December 2022, and it’s scheduled to run until March 2028.
3. Zerlasiran
Zerlasiran works the same way as olpasiran. But it’s made by a different company, and it’s working through clinical trials at a different pace.
Like olpasiran and pelacarsen, zerlasiran is an injectable medication that’s administered under the skin. A phase 2 study of zerlasiran reported over 80% reduction in Lp(a) when the medication was given every 4 to 6 months. But currently there are no phase 3 studies underway.
4. Lepodisiran
Lepodisiran works in a similar way to zerlasiran and olpasiran. Like the other medications we’ve discussed above, lepodisiran is given as an injection under the skin. In a phase 2 study published in 2025, lepodisiran reduced Lp(a) by nearly 95%.
A phase 3 study of lepodisiran is currently underway. The study will wrap up in 2029. So there’s still a long way to go before we have more information about this one.
5. Muvalaplin
Muvalaplin is a once-daily oral pill. The fact that it’s not an injectable medication is a big part of what makes it unique. It works differently from the injections. It stops apo(a) from attaching to an LDL particle. This prevents new Lp(a) particles from forming.
A phase 2 trial of muvalaplin was reported in 2025. In this study, muvalaplin reduced Lp(a) by about 86 %. A phase 3 study is in progress, but won’t be completed until 2031.
6. HRS-5346 / MK-7262
HRS-5346 and MK-7262 are two names for the same experimental pill. This medication works much like muvalaplin.
At a medical conference in August 2026, researchers in China reported that the medication lowered Lp(a) by as much as 86% in a phase 2 study. The full results haven’t yet been published in a peer-reviewed medical journal. Another phase 2 study is expected to finish in late 2027.
How is high lipoprotein(a) currently treated?
High Lp(a) levels are usually caused by your genetics, not your diet or lifestyle. So, without any FDA-approved medications available, treatment for high Lp(a) levels focuses on minimizing other risk factors for heart disease.
There are a few conditions that are linked to higher Lp(a) levels. So treating these conditions may improve your levels:
Inflammatory health conditions, such as rheumatoid arthritis
Certain types of chronic kidney disease
A procedure called lipoprotein apheresis is another treatment. Lipoprotein apheresis uses a machine to filter LDL cholesterol and Lp(a) out of your blood. It’s an effective treatment for severe cases of high Lp(a). It’s even FDA approved for this purpose. But it’s time-consuming, expensive, and hard to find treatment centers that use it. So it’s not always a realistic option.
Certain medications are sometimes taken off-label in an attempt to lower Lp(a):
PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent) may lower Lp(a) by up to 30%. These medications are given by injection.
Inclisiran (Leqvio) is similar to PCSK9 inhibitors. It may lower Lp(a) by up to 26%.
Niacin is a form of vitamin B3 that can lower Lp(a) when taken in high doses. But adding it to statin treatment doesn’t prevent more heart attacks or strokes. It can also cause serious side effects. So experts don’t recommend it to treat high Lp(a).
Estrogen pills used to treat menopause symptoms can reduce Lp(a) by as much as 20%. But lowering Lp(a) this way hasn’t been shown to prevent heart attacks or strokes. So experts don’t recommend estrogen just to treat high Lp(a).
Risk reduction
Even though you can’t change your Lp(a) levels, heart-related risk factors that you can manage include:
High cholesterol
High blood pressure
Diabetes
Smoking
Physical activity and exercise
Nutrition
Body weight
Frequently asked questions
Lipoprotein(a), or Lp(a), is measured through a simple blood test. It’s not part of the usual cholesterol panel, but it can be drawn at the same time. The American Heart Association recommends that every adult have their Lp(a) checked at least once. A level above 50 mg/dL (or 125 nmol/L) is considered high.
Statins don’t lower Lp(a), but they have other important benefits. Statins lower LDL cholesterol, reduce inflammation in the heart arteries, and can help prevent cardiovascular disease. Whether you need a statin depends on your LDL level and other risk factors. If you have high Lp(a), talk with your healthcare team about your overall risk for heart disease and stroke.
Since Lp(a) is mostly genetic, it cannot usually be reversed. New medications may change that. But researchers are still studying whether they prevent heart attacks and strokes. Those results will help determine whether the medications become available.
An Lp(a) level of 50 mg/dL or higher — or 125 nmol/L or higher — is considered high. The risk of heart disease generally rises as the level increases. But there’s no single number that means immediate danger. Your overall risk also depends on your LDL (“bad”) cholesterol, blood pressure, smoking history, and other health conditions. Talk with a healthcare professional about what your Lp(a) result means for you.
Lipoprotein(a), or Lp(a), is measured through a simple blood test. It’s not part of the usual cholesterol panel, but it can be drawn at the same time. The American Heart Association recommends that every adult have their Lp(a) checked at least once. A level above 50 mg/dL (or 125 nmol/L) is considered high.
Statins don’t lower Lp(a), but they have other important benefits. Statins lower LDL cholesterol, reduce inflammation in the heart arteries, and can help prevent cardiovascular disease. Whether you need a statin depends on your LDL level and other risk factors. If you have high Lp(a), talk with your healthcare team about your overall risk for heart disease and stroke.
Since Lp(a) is mostly genetic, it cannot usually be reversed. New medications may change that. But researchers are still studying whether they prevent heart attacks and strokes. Those results will help determine whether the medications become available.
An Lp(a) level of 50 mg/dL or higher — or 125 nmol/L or higher — is considered high. The risk of heart disease generally rises as the level increases. But there’s no single number that means immediate danger. Your overall risk also depends on your LDL (“bad”) cholesterol, blood pressure, smoking history, and other health conditions. Talk with a healthcare professional about what your Lp(a) result means for you.
The bottom line
Lipoprotein(a), or Lp(a), is a form of “bad” cholesterol. Your Lp(a) level is mostly set by your genes. High levels raise your risk of heart disease and stroke. Several medications that lower Lp(a) are being studied, but none are FDA approved yet. If you have high Lp(a), work with a healthcare professional to manage your other risks, including high low-density lipoprotein (LDL) cholesterol and blood pressure. Healthy habits like good nutrition and exercise will also help protect your heart, even if they don’t lower Lp(a).
Why trust our experts?


References
American Heart Association. (n.d.). Lipoprotein(a).
Blumenthal, R. S., et al. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.
Cho, L., et al. 2026. Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). The New England Journal of Medicine.
ClinicalTrials.gov. (2026). A clinical trial of MK-7262 and enlicitide in participants with high lipoprotein(a) (MK-7262-004). National Library of Medicine.
ClinicalTrials.gov. (2026). A study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) - ACCLAIM-Lp(a). National Library of Medicine.
ClinicalTrials.gov. (2026). Assessing the impact of muvalaplin on major cardiovascular events in adults with elevated lipoprotein(a) (MOVE-Lp(a)). National Library of Medicine.
ClinicalTrials.gov. (2026). Olpasiran trials of cardiovascular events and lipoprotein(a) reduction (OCEAN(a)) - outcomes trial. National Library of Medicine.
García-Gómez, C., et al. (2017). Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. Journal of Clinical Lipidology.
Hopewell, J. C., et al. (2018). The role of lipoprotein (a) in chronic kidney disease. Journal of Lipid Research.
Katsiki, N., et al. (2023). Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals.
Kronenberg, F., et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal.
Nicholls, S. J., et al. (2025). Oral muvalaplin for lowering of lipoprotein(a): A randomized clinical trial. JAMA.
Nissen, S. E., et al. (2025). Lepodisiran — A long-duration small interfering RNA targeting lipoprotein(a). The New England Journal of Medicine.
Nissen, S. E., et al. (2024). Zerlasiran—A small-interfering RNA targeting lipoprotein(a): A phase 2 randomized clinical trial. JAMA.
Nudy, M., et al. (2025). Long-term changes to cardiovascular biomarkers after hormone therapy in the Women’s Health Initiative hormone therapy clinical trials. Obstetrics & Gynecology.
Nugent, A. K., et al. (2020). Lipoprotein apheresis: First FDA indicated treatment for elevated lipoprotein(a). Journal of Clinical Cardiology.
O’Donoghue, M. L., et al. (2018). Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: Insights from the FOURIER. Circulation.
O’Donoghue, M. L., et al. (2022). Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. The New England Journal of Medicine.
O’Donoghue, M. L., et al. (2022). Study design and rationale for the olpasiran trials of cardiovascular events and lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal.
O’Donoghue, M. L., et al. (2024). The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results. Journal of the American College of Cardiology.
Schaffer, R. (2023). The potential next pathway to target in CVD prevention: ‘Common’ elevated Lp(a). Healio News.
Sosnowska, B., et al. (2022). Targeted treatment against lipoprotein (a): The coming breakthrough in lipid lowering therapy. Pharmaceuticals.
The HPS2-THRIVE Collaborative Group. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. The New England Journal of Medicine.
Thompson, G., et al. (2019). Current role of lipoprotein apheresis. Current Atherosclerosis Reports.
Tsimikas, S., et al. (2020). Lipoprotein(a) reduction in persons with cardiovascular disease. The New England Journal of Medicine.
Yan, J. H., et al. (2025). Pharmacokinetics and safety of pelacarsen, a GalNAc3 ‐conjugated antisense oligonucleotide targeting apo(a), in participants with mild hepatic impairment. Clinical and Translational Science.
Zhu, D. (2026). Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study. ESC 365.










